Table 11. Lipid-controlling efficacy and pharmacological features of currently used statins.

		Lovastatin	Pravastatin	Simvasattin	Fluvastatin	Atorvastatin	Rosuvastatin	Pitavastatin
Daily dose, mg		20–40	10–40*	20–40	20–80	10–80	5–20†	1–4
LDL-C reduction, %
	24–28	20	20		40			1
	30–36	40	40	20	80	10		2
	39–45	80		40		20	5–10	4
	46–52					40–80	20
Metabolism		CYP3A4	sulfonation	CYP3A4	CYP2C9	CYP3A4	CYP2C9	Glucuronidation (partial CYP2C9)
Protin binding, %		>95	43–67	95–98	98	98	88	>99
Half-life, hr		2–4	2–3	1–3	0.5–3	13–30	19	12
Hydrophilicity		−	+	−	−	−	+	−
Elimination		Hepatobiliary	Hepatobiliary	Hepatobiliary	Hepatobiliary	Hepatobiliary	Hepatobiliary	Hepatobiliary
Renal elimination fraction, %		10	20	13	<6	<2	28	15

LDL-C, low density lipoprotein cholesterol; CYP, cytochrome P450.

^*40–80 mg in Caucasian countries.

^†5–40 mg in Caucasian countries.